The DOI matches its Crossref record; 189 of the 189 references it cites were found in a registry or an index.
Turning cold tumors hot: from molecular mechanisms to clinical applications
Abstract
Immune checkpoint blockade (ICB) therapies have achieved clinical benefit, but most 'immune-cold' solid tumors are not responsive. The diversity of immune evasion mechanisms remains a key obstacle in turning nonresponsive 'cold' tumors into responsive 'hot' ones. Therefore, exploring the mechanisms of such transitions and tumor immunotyping can provide significant insights into designing effective therapeutic strategies against cancer. Here, we focus on the latest advances regarding local and systemic regulatory mechanisms of immune responses in cold and hot tumors. We also highlight the necessity for tumor immunotyping through the assessment of multiple immunological variables using various diagnostic techniques and biomarkers. Finally, we discuss the challenges and potential clinical applications of immunophenotyping to turn cold tumors hot, which may further guide combined immunotherapies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As noted above, based on their TME, tumors can be categorized into two general types: ‘hot’ tumors, distinguished by an immunosupportive TME and a positive response to immunotherapy, and ‘cold’ or non-immune reactive tumors exhibiting a poor response to immunotherapy and characterized by an immunosuppressive TME (Zhang et al., 2022; Benoit et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Zhang et al., 2022
Citations
Cites
1 retracted
Kamiya, A., Hayama, Y., Kato, S., Shimomura, A., Shimomura, T., Irie, K., Kaneko, R., Yanagawa, Y., Kobayashi, K., & Ochiya, T. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0430-3 · Cited by 287
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Self-citationGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 811
CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential
Koh, C., Lee, S., Kwak, M., Kim, B., & Chung, Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01105-x · Cited by 379
“These “ hot ” tumors exhibit a more favorable response to immunotherapies than “ cold ” tumors, which lack Tc1 cell in fi ltration 28,29 .”
BackgroundTertiary lymphoid structures in anticancer immunity
Teillaud, J., Houel, A., Panouillot, M., Riffard, C., & Dieu‐Nosjean, M. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00728-0 · Cited by 322
“Finally, it is unclear whether ‘cold’ tumours that do not exhibit substantial immune cell infiltrates could be made ‘hot’ when using inducers of TLS 189 .”
Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides
Huang, D., Zhu, X., Ye, S., Zhang, J., Liao, J., Zhang, N., Zeng, X., Wang, J., Yang, B., Zhang, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06834-7 · Cited by 222
Self-citationChen, Y., Wang, D., Li, Y., Lu, Q., Si, W., Bo, Y., Chen, X., Ye, Z., Fan, H., Liu, B., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.06.009 · Cited by 229
Metadata
- Authors
- Zhang, J., Huang, D., Saw, P. E., & Song, E.
- Affiliations
- Sun Yat-sen University (CN)
- Corresponding author
- Saw, Phei Er
- Song, Erwei
- Venue
- Trends in Immunology
- Publisher
- Elsevier BV
- Published
- 2022-07
- Volume
- 43
- Issue
- 7
- Pages
- 523-545
- ISSN
- 1471-4906 (ISSN-L)
- OpenAlex
- W4281490788
- Cited by
- 534
- References
- 189
- Citations by year
- 2026: 72 · 2025: 145 · 2024: 162 · 2023: 133 · 2022: 22
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Trends in Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (81621004, 81720108029, 81930081, 91940305, 92159303)
- Guangdong Science and Technology Department (2020B1212030004, 2020B1212060018)
- Guangzhou Municipal Science and Technology Bureau (20212200003)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- cold tumors, immune evasion, immune checkpoint blockade, tumor microenvironment, immune regulation, biomarkers, combination immunotherapy, solid tumors
- MeSH terms
- Humans, Immunity, Immunotherapy, Neoplasms, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
